Shop

Description

Belkyra (marketed as Kybella in North America) represents the clinical gold standard for the non-surgical treatment of submental fullness, commonly referred to as the “double chin.” Developed by Allergan Aesthetics, this injectable solution is the first and only FDA-approved (and globally recognized) deoxycholic acid treatment designed to target and dissolve fat cells in the submental area. For aesthetic clinics, offering Belkyra is synonymous with providing patients a scientifically validated, long-term solution that eliminates the need for invasive liposuction. By permanently reducing fat deposits under the chin, Belkyra offers a transformative contouring outcome that enhances facial profile and jawline definition.

The Science of Deoxycholic Acid

Belkyra contains a synthetic, pharmaceutical-grade version of deoxycholic acid. In the human body, deoxycholic acid is a naturally occurring secondary bile acid that plays a critical role in the emulsification and digestion of dietary fats.

When formulated for aesthetic use, this substance acts as a potent cytolytic agent. Once injected into the subcutaneous adipose tissue, it disrupts the cell membrane of the adipocytes (fat cells). This process, known as adipocytolysis, leads to the irreversible destruction of the cell. Once the cell membrane is lysed, the fatty contents are released and naturally metabolized by the body’s lymphatic and circulatory systems. Because the adipocytes themselves are destroyed rather than just shrunken, the reduction in submental fat is permanent, provided the patient maintains a stable weight.

Key Clinical Benefits

• Permanence: Unlike traditional lipolytic cocktails that may require constant maintenance, Belkyra destroys fat cells. Once the desired contour is achieved, the results are maintained long-term.

• Precision Contouring: The product allows for highly localized treatment, enabling the practitioner to contour the jawline and chin area with millimeter precision, respecting the patient’s unique facial anatomy.

• Non-Invasive Profile: Eliminates the risks associated with surgical submental liposuction, such as general anesthesia, scarring, extensive recovery time, and surgical complications.

• Patient Satisfaction: High clinical success rates and improved psychological outcomes related to patient self-perception of their facial profile.

Indications and Patient Selection

Belkyra is specifically indicated for the improvement of the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

• Ideal Candidates: Patients with good skin elasticity who have localized submental adipose tissue.

• Contraindications: Patients with active infection in the treatment area, excessive skin laxity (platysmal bands may require different approaches), or history of dysphagia (difficulty swallowing).

Technical Specifications

Clinical Administration Protocol

Success with Belkyra is fundamentally dependent on precise anatomical mapping and adherence to the grid technique.

1. Marking the Treatment Area: With the patient in an upright, relaxed position, the practitioner must mark the submental fat pad. Using a marking grid template is highly recommended to ensure consistent and safe injection intervals.

2. Safety Zone Identification: Practitioners must identify the mandibular border to avoid injecting too close to the marginal mandibular nerve. Avoiding the submandibular glands is also paramount to patient safety.

3. Dosing: The standard dose is 2mg per cm² (0.2 mL of Belkyra). The treatment involves multiple small injections (0.2 mL each) spaced 1cm apart within the marked grid.

4. Number of Sessions: While results are visible after the first session, a series of 2 to 6 treatments is typically required, spaced at least 4 to 6 weeks apart, depending on the patient’s baseline fat volume.

Standard Dosing Table

Managing Patient Expectations (The Inflammatory Response)

It is vital to communicate the “inflammatory phase” to patients. Unlike other treatments, Belkyra requires an inflammatory response to effectively destroy fat cells and remodel the tissue.

• Swelling: This is the most common side effect and is an expected part of the mechanism of action. Patients should be warned that the submental area will appear “fuller” or swollen for the first 3 to 7 days post-treatment.

• Bruising: Small amounts of bruising at the injection sites are common but typically resolve quickly.

• Numbness: Temporary numbness or paresthesia in the submental area is frequently reported and resolves spontaneously within a few weeks.

Frequently Asked Questions (FAQ)

Q: Is Belkyra painful?

A: Patients often experience a burning or stinging sensation during and immediately following the injection as the deoxycholic acid begins to work. The use of topical anesthetics or ice packs prior to the procedure is standard practice to improve patient comfort.

Q: Can Belkyra be used on the body (e.g., abdomen, thighs)?

A: Belkyra is FDA-approved specifically for the submental area. While some clinicians explore “off-label” use for other body zones, Belkyra is optimized and safety-tested specifically for the submental fat pocket. Large-volume body injections carry different risks and protocols.

Q: What is the difference between Belkyra and fat-dissolving cocktails?

A: Most “fat-dissolving” cocktails (like Phosphatidylcholine/Deoxycholate blends) are cosmetic mesotherapy products. Belkyra is a pharmaceutical-grade, single-ingredient (Deoxycholic Acid) injectable that has undergone rigorous clinical trials for safety and efficacy.

Q: How soon will the patient see results?

A: Visible reduction usually occurs after the second session. Because the body needs time to metabolize the destroyed fat cells, the final profile improvement is typically appreciated 4 to 6 weeks after the final session.

Safety and Regulatory Disclaimer

Belkyra is a potent pharmaceutical agent. It must only be administered by a licensed healthcare professional with advanced training in facial anatomy and injectable techniques.

• Mandatory Training: Practitioners must be familiar with the “danger zones” of the neck, specifically the marginal mandibular branch of the facial nerve, to prevent transient facial asymmetry.

• Contraindications: Do not inject into the thyroid gland, salivary glands, or near the hyoid bone.

• Documentation: Practitioners should maintain detailed records of the treatment grid and volume injected for every session to track progress and ensure patient safety.

Medical Disclaimer: The information provided herein is for professional educational purposes only and does not supersede the product’s official Package Insert (PI) or Instructions for Use (IFU). The practitioner assumes full clinical responsibility for patient assessment, informed consent, and technique. We are not liable for any clinical outcomes or complications arising from the administration of this product. By using this product, the clinician acknowledges they possess the requisite training and certifications.

Wholesale & Clinical Integration

We provide access to original Belkyra (Kybella) stock, ensuring complete authenticity and rigorous adherence to cold-chain storage and pharmaceutical integrity standards. Integrating Belkyra into your clinic’s menu provides a premium, high-margin, and highly effective service that targets one of the most common aesthetic concerns of the modern patient. For bulk clinic pricing, licensing verification, or to request technical documentation for your regulatory files, please contact our wholesale division. Elevate your clinical offering with the gold standard in submental fat reduction.